Cell Source, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLCS research report →
About the company
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses.
- CEO
- Itamar Shimrat
- IPO
- 2014
- Employees
- 1
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $41.89M
- P/E
- -6.20
- P/S
- 0.00
- P/B
- -2.07
- EV/EBITDA
- -14.40
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 27.73%
- ROIC
- 44.09%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,771,046 · 10.34%
- EPS
- $-0.15 · 11.76%
- Op Income
- $-3,848,500
- FCF YoY
- -14.32%
- 52W High
- $2.25
- 52W Low
- $0.27
- 50D MA
- $0.82
- 200D MA
- $0.67
- Beta
- -157.98
- Avg Volume
- 2.68K
Get TickerSpark's AI analysis on CLCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 22 | Verstraete George | other | 0 |
| Aug 9, 21 | Soave Darlene | other | 800,000 |
| Jun 30, 21 | ZOLTY DAVID | other | 4,860 |
| Jun 30, 21 | Soave Darlene | other | 59,507 |
| Jun 30, 21 | Brown Dennis M | other | 2,976 |
| Jun 30, 21 | FRIEDMAN BENZION ABRAHAM | other | 19,440 |
| Dec 29, 20 | ZOLTY DAVID | other | 4,941 |
| Jun 30, 20 | ZOLTY DAVID | other | 4,887 |
| Dec 31, 19 | ZOLTY DAVID | other | 6,420 |
| Jun 26, 19 | ZOLTY DAVID | other | 1,339 |
Our CLCS coverage
Recent articles, reports, and earnings notes.
No research on CLCS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLCS report →Similar companies
Peers in the same neighborhood.